ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.

ABSTRACT:

Background

An increasing number of trials indicate that treatment outcomes in cancer patients with metastatic disease are improved when targeted treatments are matched with druggable genomic alterations in individual patients (pts). An estimated 30-80% of advanced solid tumors harbor actionable genomic alterations. However, the efficacy of personalized cancer treatment is still scarcely investigated in larger, controlled trials due to the low frequency and heterogenous distribution of druggable alterations among different histologic tumor types. Therefore, the overall effect of targeted cancer treatment on clinical outcomes still needs investigation.

Study design/methods

ProTarget is a national, non-randomized, multi-drug, open-label, pan-cancer phase 2 trial aiming to inves

SUBMITTER: Kringelbach T 

PROVIDER: S-EPMC9948467 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature